author-photo

Albert Hallsworth

Institute of Cancer Research

25

Papers

630

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Orally-bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

2020
Show All
- Source
- Cite
- Save
Citations (11)
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.

2020 Oncotarget
Show All
- Source
- Cite
- Save
Citations (4)
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.

2020 Blood Advances
Show All
- Source
- Cite
- Save
Citations (5)
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.

2020 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (5)
In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis.

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (17)
Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform

2017 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (6)
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (17)
HG-67PRECLINICAL EFFICACY OF ALK2 INHIBITORS IN ACVR1 MUTANT DIPG

2016 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (1)
Molecular and In Vivo Characterization of Cancer-Propagating Cells Derived from MYCN-Dependent Medulloblastoma

2015 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (14)
Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (35)